Browsing Tag
Novartis
83 posts
Blackstone Life Sciences and Novartis launch Anthos Therapeutics to target high-risk cardiovascular diseases
In a strategic partnership aimed at advancing cardiovascular treatments, Blackstone Life Sciences has teamed up with Swiss pharmaceutical…
Novartis secures FDA approval for Egaten as fascioliasis treatment
Novartis has achieved a significant milestone with the FDA’s approval of Egaten (triclabendazole) for the treatment of fascioliasis…
Novartis aims to strengthen cell therapy capabilities with CellforCure acquisition
Novartis has announced plans to acquire CellforCure, a French contract development and manufacturing organisation (CDMO), from LFB for…
Novartis completes $2.1bn acquisition of Endocyte to boost cancer treatment capabilities
Swiss pharmaceutical giant Novartis has officially closed its $2.1 billion acquisition of US-based biopharma company Endocyte, solidifying its…
Novartis’ Kisqali plus endocrine therapy shows significant PFS benefits in advanced breast cancer trials
Swiss pharmaceutical giant Novartis has announced that its breast cancer drug, Kisqali (ribociclib), when used in combination with…
Novartis secures EC approval for Gilenya in pediatric multiple sclerosis treatment
Novartis has announced that the European Commission has expanded the approval of its multiple sclerosis drug, Gilenya (fingolimod),…
Pfizer, AbbVie settle global IP for Humira biosimilar, paving way for European launch
In a significant step towards expanding biosimilar access, Pfizer and AbbVie have resolved all global intellectual property disputes…
Spark Therapeutics’ Luxturna gains EU approval as first gene therapy for inherited retinal disease
In a significant breakthrough for treating inherited vision loss, Pennsylvania-based Spark Therapeutics has received European Commission (EC) approval…
Novartis’ Promacta approved by FDA for first-line treatment of severe aplastic anemia
The U.S. Food and Drug Administration (FDA) has granted an expanded indication for Novartis’ Promacta (eltrombopag), approving it…
EC approves dosing flexibility for Novartis’s Cosentyx in psoriatic arthritis treatment
The European Commission (EC) has granted Novartis approval for a significant update to the label of its psoriatic…